Tuesday, March 1, 2011
4SC AG, of Planegg-Martinsried, Germany, reported final data from its ENTRANCE Phase IIa study of vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, in inflammatory bowel disease, which supported previously reported top-line primary endpoint data showing a total response rate of 88.5 percent. Secondary endpoint data included Crohn's Disease Activity Index and the Colitis Activity Index scores in line with the assignment of patients to the complete, partial and nonresponder categories. All 26 evaluable patients, excluding the three nonresponders, reached a relapse-free prednisolone dose significantly lower than their individual threshold doses at which they experienced relapses prior to entering the study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.